ProteinQure Inc.
25.3.2024 05:03:30 CET | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
Developed through ProteinQure's cutting-edge computational platform, the innovative SORT1 targeting PDC is a novel peptide attached to a highly potent chemotherapeutic agent. The drug candidate was tested across a broad range of breast cancer models. The results demonstrated remarkable antitumor efficacy, including cancers resistant to standard chemotherapies and antibody-drug conjugates.
"Working with the David Cescon Lab at UHN has been instrumental in validating our novel PDC's efficacy against one of the most challenging forms of breast cancer. Based on these results, we are moving our lead program forward into IND-Enabling studies and our first clinical trial," said Lucas Siow, CEO of ProteinQure. "These findings not only highlight the power of our computational drug design platform but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery."
ProteinQure's collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community.
"We are excited to present this data at AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups," stated Dr. David Cescon, head of the lab at UHN. "The success of this unique PDC in diverse PDX models is a testament to the potential of combining advanced computational techniques, precision oncology, and our labs' robust preclinical platform".
Funding for parts of this work included contributions from IRAP-Canada and the INOVAIT program based out of Sunnybrook Hospital.
Poster Presentation Details:
Title: In-vivo efficacy of a novel peptide-conjugated drug in patient-derived xenograft models of breast cancer
Session Title: New Targets
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5911
Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre
About ProteinQure
ProteinQure is a pioneering startup specializing in the computational design of peptide drugs utilizing state-of-the-art artificial intelligence and molecular simulation technologies. With a focus on precision medicine, ProteinQure is dedicated to transforming the landscape of drug development and ushering in a new era of targeted effective treatments.
About the David Cescon Lab at UHN
The David Cescon Lab at the University Health Network is a leader in breast cancer research, focusing on the mechanisms of cancer progression and resistance to therapy. Through cutting-edge pre-clinical and clinical research and collaborations, the lab develops novel therapeutic strategies aimed at improving outcomes for cancer patients worldwide.
For further information, please contact:
Lucas Siow - CEO of ProteinQure - press@proteinqure.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
SOURCE: ProteinQure Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI and Coppercore Inc. Announce Tokenization of High-Grade Copper Resources into Coppercoin(TM)31.3.2026 15:15:00 CEST | Press release
$100 Million in Initial Coppercoin™ Issuance to Set Industry Standard in Tokenized Copper PHILADELPHIA, PA / ACCESS Newswire / March 31, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, and Coppercore Inc. ("Coppercore") today announced the closing of a definitive agreement to digitize and tokenize significant copper resources. The transaction enables Datavault AI to deploy its patented IDE®, DataScore®, and DataValue® blockchain tokenization platform to create Coppercoin™ digital tokens representing pro-rata ownership interests in the underlying in-ground resources. The initial program targets the minting of $100 million or more in Digital Copper Tokens. Coppercoin™ tokens are structured such that each token corresponds to five pounds of underlying high-grade copper resources, with pricing directly linked to the COMEX copper benchmark on a pe
AccessPay Accelerates Growth With Majority Investment From Leading Software Investor, Accel-KKR31.3.2026 10:00:00 CEST | Press release
Financial backing enables AccessPay to scale services for enterprise clients and drive innovation in finance operations MANCHESTER, UK / ACCESS Newswire / March 31, 2026 / AccessPay, a leading bank integration and payment automation provider, has secured a majority investment from Accel-KKR, a prominent global private equity firm specialising in enterprise technology and software companies. The investment is expected to enable AccessPay to fuel the next phase of growth and further its ambition to become a world-class SaaS business driving innovation in the office of the CFO. The investment also opens the door for AccessPay to pursue growth via strategic acquisitions. The office of the CFO faces an increasingly testing operating environment. Alongside cost pressures, increased cyber threats, and a volatile geopolitical climate, AI is fundamentally rewiring finance operating practices. A global McKinsey survey of CFOs from late 2025 reported that 44% of survey respondents had identified
The World's First Agentic CMS Just Got Smarter: Kontent.ai Launches Expert Agents31.3.2026 09:00:00 CEST | Press release
Kontent.ai, the team behind the world's first Agentic CMS, today announced the launch of Expert Agents: purpose-built AI agents that bring deep, specialized intelligence to the content operations teams manage every day. Expert Agents work continuously across content workflows, handling everything that doesn't require human judgment. They can be configured by anyone using simple natural language prompts. BRNO, CZ / ACCESS Newswire / March 31, 2026 / Expert Agents help organizations move faster than ever before, augmenting teams without adding headcount, accelerating campaign launches across markets, improving content performance at scale, and reducing regulatory and compliance risk across even the largest content inventories. The launch marks the next step in Kontent.ai's Agentic CMS vision: a platform where AI agents are embedded directly into the operational layer of content management. At its core, the Agentic CMS combines two layers of intelligence: the Main Agent, which lets teams
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy30.3.2026 16:55:00 CEST | Press release
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development. Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate
CORRECTION: Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World30.3.2026 16:25:00 CEST | Press release
This Press Release updates the previous version that had incorrect information Datavault AI Inc., Mandela Dlamini & Manaway L.L.C., and Unity Reserve Holdings L.L.C. Launch MUSD Stablecoin to Advance Financial Inclusion and Honor Nelson Mandela's Legacy PHILADELPHIA, PA / ACCESS Newswire / March 30, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset ("RWA") tokenization technologies, Mandela Dlamini & Manaway L.L.C., a Wyoming, USA-based entity ("MDM LLC") dedicated to advancing Nelson Mandela's vision of equality, dignity, and economic empowerment, and Unity Reserve Holdings L.L.C. ("Unity Reserve"), today announced the official launch of Mandela Dollar ("MUSD"), a new USD-pegged stablecoin designed to promote financial inclusion for underserved communities globally. MUSD is designed to serve as a transparent, secure, and accessible digital dollar built on blockchain technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom